{
  "docId": "019de071-41d7-735b-bdce-76898f0847d2",
  "docSlug": "eaafde7daeccaea38d88b7264ade91c5",
  "documentTitle": "Erasca | IPO Presentation Deck | 46 slides",
  "authorId": "erasca",
  "authorName": "Erasca",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 40,
  "pageCount": 46,
  "prevPage": 39,
  "nextPage": 41,
  "slideType": "other",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 14,
  "notes": "TGI = Tumor Growth Inhibition. CDX = Cell line-derived xenograft. MIA PaCa-2 is a human pancreatic cancer cell line.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-41d7-735b-bdce-76898f0847d2/40",
  "deckHref": "/decks/019de071-41d7-735b-bdce-76898f0847d2",
  "deckJsonHref": "/decks/019de071-41d7-735b-bdce-76898f0847d2.json",
  "deckAnchorHref": "/decks/019de071-41d7-735b-bdce-76898f0847d2#slide-40",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.45,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "chart",
      "text": "TGI in subcutaneous KRAS G12C pancreatic cancer CDX MIA PaCa-2",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "383d6ce4-6d97-4599-9e00-4711e4d386b3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.45,
        "x": 0.52,
        "y": 0.25
      },
      "kind": "chart",
      "text": "% body weight change in subcutaneous KRAS G12C pancreatic cancer CDX MIA PaCa-2",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "86b19b45-42ad-4c84-83cb-3ba1c978e084",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "paragraph",
      "text": "Subcutaneous KRAS G12C pancreatic cancer CDX MIA PaCa-2",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "900794aa-ba56-4f3a-9a4b-d5ed444e2f0e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "ERAS-3490 and ERAS-3691 showed comparable to superior TGI relative to a reference compound in KRAS G12Ci sensitive model and was well tolerated",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5a5a9a79-f0dc-48dd-9293-f2debf90da90",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Waterfall chart",
      "slug": "waterfall-chart",
      "agent": null,
      "layer": "slide",
      "matchId": "fc545f07-7eec-4191-baf4-08920504ee03",
      "evidence": "chart/line: % body weight change in subcutaneous KRAS G12C pancreatic cancer CDX MIA PaCa-2, chart/line: TGI in subcutaneous KRAS G12C pancreatic cancer CDX MIA PaCa-2",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}